Evidence for Use of Tenofovir in Pregnancy to Prevent Perinatal Transmission of Hepatitis B InfectionSYLVESTER-ARMSTRONG, KENDRA R. MD; DUFF, WILLIAM PATRICK MDClinical Obstetrics and Gynecology: March 27, 2019 - Volume Publish Ahead of Print - Issue - p doi: 10.1097/GRF.0000000000000438 Original Article: PDF Only Buy PAP Abstract Author InformationAuthors Article MetricsMetrics Perinatal transmission of hepatitis B virus continues to be a serious global public health concern. Transmission failures are related to high maternal viremia. Several antiviral therapies reduce maternal viremia around the time of delivery and decrease maternal-to-child-transmission. This chapter is a review of current studies that, ultimately, have provided strong evidence for the efficacy and safety of 3 antiviral drugs in pregnancy—lamivudine, telbivudine and tenofovir. The latter drug is the particular focus of this chapter which will show that tenofovir is the preferred antiviral therapy in pregnant women because of its potency, safety profile, and low risk of resistance. Department of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville, Florida The authors declare that they have nothing to disclose. Correspondence: Kendra R. Sylvester-Armstrong, MD, P.O. Box 100294, Gainesville, FL. E-mail: ksyL06@ufl.edu Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.